{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:22:13Z","timestamp":1782944533675,"version":"3.54.5"},"reference-count":262,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.critrevonc.2013.08.010","type":"journal-article","created":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T14:02:32Z","timestamp":1378044152000},"page":"262-283","source":"Crossref","is-referenced-by-count":21,"title":["Toll-like receptors in lymphoid malignancies: Double-edged sword"],"prefix":"10.1016","volume":"89","author":[{"given":"Sara","family":"Harsini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maani","family":"Beigy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Akhavan-Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2013.08.010_bib0005","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2008-02-140673","article-title":"Toll-like receptors: lessons to learn from normal and malignant human B cells","volume":"12","author":"Chiron","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/med.20214","article-title":"Prophylactic and therapeutic implications of Toll-like receptor ligands","volume":"32","author":"Hedayat","year":"2010","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0015","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1073\/pnas.0631696100","article-title":"Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7","volume":"100","author":"Lee","year":"2003","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/08830185.2012.706761","article-title":"Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities","volume":"31","author":"Moghimpour Bijani","year":"2012","journal-title":"International Reviews of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2174\/156652409787847182","article-title":"Toll-like receptors and their role in hematologic malignancies","volume":"9","author":"Wolska","year":"2009","journal-title":"Current Molecular Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling","volume":"19","author":"Kawai","year":"2007","journal-title":"Seminars in Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0035","first-page":"406","article-title":"Toll-like receptors in the induction of the innate immune response","author":"Aderem","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0040","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-\u03baB by Toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.it.2005.06.009","article-title":"TLR signalling and activation of IRFs: revisiting old friends from the NF-\u03baB pathway","volume":"26","author":"Moynagh","year":"2005","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0055","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3324\/haematol.2011.044792","article-title":"Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients","volume":"96","author":"Arvaniti","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0060","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.micinf.2004.08.018","article-title":"Toll-like receptors: linking innate and adaptive immunity","volume":"6","author":"Pasare","year":"2004","journal-title":"Microbes and Infection"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1189\/jlb.0104016","article-title":"Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells","volume":"76","author":"Spaner","year":"2004","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0070","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-\u03baB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0080","first-page":"177","article-title":"Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer","volume":"61","author":"Neill","year":"2009","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.intimp.2006.02.005","article-title":"Therapeutic targeting of pattern-recognition receptors","volume":"6","author":"Rezaei","year":"2006","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7150\/ijbs.6.675","article-title":"The application of Toll like receptors for cancer therapy","volume":"6","author":"So","year":"2010","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2404456","article-title":"Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia","volume":"21","author":"Spaner","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0100","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/138945010790980376","article-title":"New targets of therapy in T-cell lymphomas","volume":"11","author":"Erter","year":"2010","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0105","first-page":"927","article-title":"Toll-like receptor modulators: a patent review (2006\u20132010)","volume":"21","author":"Basith","year":"2011","journal-title":"Expert Opinions"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0110","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00011-010-0208-2","article-title":"Important aspects of Toll-like receptors, ligands and their signaling pathways","volume":"59","author":"Chang","year":"2010","journal-title":"Inflammation Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0115","first-page":"5","article-title":"Advances in Toll-like receptor signaling","volume":"1","author":"Krishnan","year":"2012","journal-title":"Advances in Systems Biology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0120","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.4049\/jimmunol.179.6.3472","article-title":"Engagement of TLR3, TLR7, and NKG2D regulate IFN-\u03b3 secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12","volume":"179","author":"Girart","year":"2007","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0125","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.4049\/jimmunol.0804318","article-title":"TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells","volume":"183","author":"Holm","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/CVI.00257-07","article-title":"Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands","volume":"15","author":"Fitzner","year":"2008","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0135","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.4049\/jimmunol.180.5.3399","article-title":"Human lymphatic endothelial cells express multiple functional TLRs","volume":"180","author":"Pegu","year":"2008","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.jid.5700559","article-title":"Human keratinocyte Toll-like receptors promote distinct immune responses","volume":"127","author":"Miller","year":"2007","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0145","doi-asserted-by":"crossref","first-page":"e42583","DOI":"10.1371\/journal.pone.0042583","article-title":"RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response","volume":"7","author":"Guo","year":"2012","journal-title":"PloS ONE"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0150","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.vaccine.2009.01.071","article-title":"Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer","volume":"27","author":"Jasani","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/15476910903286733","article-title":"Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists","volume":"6","author":"Hamm","year":"2009","journal-title":"Journal of Immunotoxicology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0160","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.onc.1210913","article-title":"TLR7 and TLR8 as targets in cancer therapy","volume":"27","author":"Sch\u00f6n","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0170","doi-asserted-by":"crossref","DOI":"10.1038\/ni0602-499","article-title":"Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848","volume":"3","author":"Jurk","year":"2002","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0175","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.23280","article-title":"Prolonged subcutaneous administration of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies","volume":"87","author":"Weigel","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1665-2681(19)31786-7","article-title":"Current and future treatment options for HCV","volume":"8","author":"Kronenberger","year":"2009","journal-title":"Annals of Hepatology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1465-9921-13-53","article-title":"Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis","volume":"13","author":"Greiff","year":"2012","journal-title":"Respiratory Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0190","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3109\/10428194.2011.582202","article-title":"Synergistic enhancement of cellular immune responses by the novel Toll receptor 7\/8 agonist 3M-007 and interferon-gamma: implications for therapy of cutaneous T-cell lymphoma","volume":"52","author":"Wysocka","year":"2011","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0195","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0200","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0205","first-page":"5595","article-title":"CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations","volume":"63","author":"van Ojik","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm0897-849","article-title":"Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants","volume":"3","author":"Roman","year":"1997","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0215","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.164.5.2372","article-title":"CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses","volume":"164","author":"Vabulas","year":"2000","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0220","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0225","first-page":"5898","article-title":"CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry","volume":"160","author":"Yi","year":"1998","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0230","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/1078-0432.CCR-03-0239","article-title":"Characterization of effusion-infiltrating T cells: benign versus malignant effusions","volume":"10","author":"Atanackovic","year":"2004","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0235","first-page":"3","article-title":"TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism","author":"Noack","year":"2012","journal-title":"Cell Death and Disease"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0240","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1016\/j.vaccine.2008.06.094","article-title":"Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia","volume":"26","author":"K\u00f6chling","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0245","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1042\/BST0351461","article-title":"Synthetic agonists of Toll-like receptors 7, 8 and 9","volume":"35","author":"Agrawal","year":"2007","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0250","first-page":"434","article-title":"Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy","volume":"21","author":"Kline","year":"2008","journal-title":"Drug News & Perspectives"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/14760584.8.3.293","article-title":"Vaccine adjuvants: scientific challenges and strategic initiatives","volume":"8","author":"Harandi","year":"2009","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0260","first-page":"10","article-title":"Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators","volume":"10","author":"Dorn","year":"2008","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0265","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.pharmthera.2006.05.005","article-title":"Strategies for targeting T-cells in allergic diseases and asthma","volume":"112","author":"Heijink","year":"2006","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0270","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ibd.23019","article-title":"Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity","volume":"19","author":"Musch","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0275","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.2009.07773.x","article-title":"study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma","volume":"146","author":"Friedberg","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0280","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0285","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.4049\/jimmunol.165.12.6889","article-title":"CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms","volume":"165","author":"Askew","year":"2000","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0290","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/onci.20696","article-title":"Trial watch: experimental Toll-like receptor agonists for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0295","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4049\/jimmunol.169.1.10","article-title":"Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins","volume":"169","author":"Takeuchi","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0300","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.4049\/jimmunol.165.12.7125","article-title":"Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses","volume":"165","author":"Wyllie","year":"2000","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2172-11-46","article-title":"Serum lipoproteins attenuate macrophage activation and Toll-like receptor stimulation by bacterial lipoproteins","volume":"11","author":"Bas","year":"2010","journal-title":"BMC Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.molmed.2005.01.003","article-title":"Chemokines and Toll-like receptors in Lyme disease pathogenesis","volume":"11","author":"Guerau-de-Arellano","year":"2005","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0315","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cell.2007.09.008","article-title":"Crystal structure of the TLR1\u2013TLR2 heterodimer induced by binding of a tri-acylated lipopeptide","volume":"130","author":"Jin","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0320","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11523-012-0213-1","article-title":"Targeting pattern recognition receptors in cancer immunotherapy","volume":"7","author":"Goutagny","year":"2005","journal-title":"Targeted Oncology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0325","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/1566524033479726","article-title":"Regulation of dendritic cell function through Toll-like receptors","volume":"3","author":"Kaisho","year":"2003","journal-title":"Current Molecular Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4161\/hv.7.0.14567","article-title":"Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: implications for peptide vaccines","volume":"7 Suppl.","author":"Mitchell","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0335","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1126\/science.285.5428.736","article-title":"Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2","volume":"285","author":"Aliprantis","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0340","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1667\/RR2657.1","article-title":"CBLB613: a TLR 2\/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure","volume":"177","author":"Singh","year":"2012","journal-title":"Radiation Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0345","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1074\/jbc.274.25.17406","article-title":"Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2","volume":"274","author":"Schwandner","year":"1999","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0350","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4049\/jimmunol.168.4.1533","article-title":"Immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent","volume":"168","author":"Massari","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0355","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/CVI.00236-12","article-title":"The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity","volume":"19","author":"Toussi","year":"2012","journal-title":"Clinical and Vaccine Immunology \u2013 CVI"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0360","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1128\/IAI.69.3.1477-1482.2001","article-title":"Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages","volume":"69","author":"Hirschfeld","year":"2001","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0365","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/86354","article-title":"Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism","volume":"2","author":"Werts","year":"2001","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/82751","article-title":"OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway","volume":"1","author":"Jeannin","year":"2000","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0375","first-page":"3920","article-title":"Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis","volume":"163","author":"Means","year":"1999","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0380","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1128\/JVI.76.17.8729-8736.2002","article-title":"Hemagglutinin protein of wild-type measles virus activates Toll-Like receptor 2 signaling","volume":"76","author":"Bieback","year":"2002","journal-title":"Journal of Virology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0385","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.4049\/jimmunol.175.7.4189","article-title":"Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus","volume":"175","author":"Aravalli","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0390","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1128\/JVI.77.8.4588-4596.2003","article-title":"Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2","volume":"77","author":"Compton","year":"2003","journal-title":"Journal of Virology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0395","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/44605","article-title":"The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens","volume":"401","author":"Underhill","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0400","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1600-0625.2008.00832.x","article-title":"Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2","volume":"18","author":"Li","year":"2009","journal-title":"Experimental Dermatology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1158\/1078-0432.CCR-10-1763","article-title":"Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells","volume":"17","author":"Lu","year":"2011","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0410","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0165-2478(97)00090-4","article-title":"T-Cell reactivity to human HSP60 in oligo-articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint","volume":"57","author":"Prakken","year":"1997","journal-title":"Immunology Letters"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0415","doi-asserted-by":"crossref","first-page":"31332","DOI":"10.1074\/jbc.M103217200","article-title":"Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll\/interleukin-1 receptor signaling pathway in innate immune cells","volume":"276","author":"Vabulas","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0420","doi-asserted-by":"crossref","first-page":"15028","DOI":"10.1074\/jbc.M200497200","article-title":"Novel signal transduction pathway utilized by extracellular HSP70","volume":"277","author":"Asea","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0425","doi-asserted-by":"crossref","first-page":"15107","DOI":"10.1074\/jbc.M111204200","article-title":"HSP70 as endogenous stimulus of the Toll\/interleukin-1 receptor signal pathway","volume":"277","author":"Vabulas","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0430","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.4049\/jimmunol.0801563","article-title":"Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling","volume":"182","author":"Huang","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0435","doi-asserted-by":"crossref","first-page":"20847","DOI":"10.1074\/jbc.M200425200","article-title":"The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2\/4 pathway","volume":"277","author":"Vabulas","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0440","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1074\/jbc.M306793200","article-title":"Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein","volume":"279","author":"Park","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0445","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1315","article-title":"Regulation of lung injury and repair by Toll-like receptors and hyaluronan","volume":"11","author":"Jiang","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0450","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-[kappa]B by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0455","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for Toll-like receptor 3","volume":"279","author":"Kariko","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0460","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0465","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1465-9921-6-116","article-title":"Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide","volume":"6","author":"MacRedmond","year":"2005","journal-title":"Respiratory Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0470","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Signaling in C3H\/HeJ and C57BL\/10ScCr Mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0475","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4049\/jimmunol.168.3.1435","article-title":"Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway","volume":"168","author":"Bulut","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0480","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1073\/pnas.042355399","article-title":"Murine retroviruses activate B cells via interaction with Toll-like receptor 4","volume":"99","author":"Rassa","year":"2002","journal-title":"Proceedings of the National Academy of Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0485","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/intimm\/dxn074","article-title":"Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3\/4-mediated IFN-beta induction","volume":"20","author":"Shingai","year":"2008","journal-title":"International Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0490","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/80833","article-title":"Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus","volume":"1","author":"Kurt-Jones","year":"2000","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0495","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.4049\/jimmunol.173.9.5688","article-title":"Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi","volume":"173","author":"Oliveira","year":"2004","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0500","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1074\/jbc.275.4.2251","article-title":"Mouse Toll-like receptor 4\u00b7MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol","volume":"275","author":"Kawasaki","year":"2000","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0505","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.imlet.2009.02.005","article-title":"Molecular events in the activation of B cells and macrophages by a non-microbial TLR4 agonist, G1-4A from Tinospora cordifolia","volume":"123","author":"Raghu","year":"2009","journal-title":"Immunology Letters"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0510","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.4049\/jimmunol.176.11.7021","article-title":"Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis","volume":"176","author":"Roelofs","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0515","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.20001858","article-title":"Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4","volume":"195","author":"Termeer","year":"2002","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0520","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.4049\/jimmunol.168.10.5233","article-title":"Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4","volume":"168","author":"Johnson","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0525","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.4049\/jimmunol.167.5.2887","article-title":"Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4","volume":"167","author":"Smiley","year":"2001","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0530","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.4049\/jimmunol.168.12.5989","article-title":"The immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4","volume":"168","author":"Guillot","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0535","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.1075565","article-title":"Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2","volume":"298","author":"Biragyn","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0540","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1074\/jbc.M100099200","article-title":"The extra domain A of fibronectin activates Toll-like receptor 4","volume":"276","author":"Okamura","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0545","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0550","doi-asserted-by":"crossref","first-page":"e30839","DOI":"10.1371\/journal.pone.0030839","article-title":"Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants","volume":"7","author":"Shanmugam","year":"2012","journal-title":"PloS ONE"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0555","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1074\/jbc.M009040200","article-title":"A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide\/Toll-like receptor 4 signaling pathway","volume":"276","author":"Lien","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0560","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0264-410X(02)00737-5","article-title":"Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice","volume":"21","author":"Przetak","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0565","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjp.0702596","article-title":"E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide","volume":"127","author":"Kawata","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0570","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/jpet.102.044487","article-title":"Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist","volume":"304","author":"Mullarkey","year":"2003","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0575","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1600-0897.2008.00654.x","article-title":"Original article: localization of Toll-like receptors on epididymal epithelial cells and spermatozoa","volume":"60","author":"Palladino","year":"2008","journal-title":"American Journal of Reproductive Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0580","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/35074106","article-title":"The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5","volume":"410","author":"Hayashi","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0585","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.1154986","article-title":"An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models","volume":"320","author":"Burdelya","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0590","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/intimm\/13.7.933","article-title":"Discrimination of bacterial lipoproteins by Toll-like receptor 6","volume":"13","author":"Takeuchi","year":"2001","journal-title":"International Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0595","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.4049\/jimmunol.167.12.7069","article-title":"Novel engagement of CD14 and multiple Toll-like receptors by group B streptococci","volume":"167","author":"Henneke","year":"2001","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0600","doi-asserted-by":"crossref","first-page":"13766","DOI":"10.1073\/pnas.250476497","article-title":"The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors","volume":"97","author":"Ozinsky","year":"2000","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0605","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0610","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0615","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1084\/jem.20050914","article-title":"Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus","volume":"202","author":"Barrat","year":"2005","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0620","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.20051696","article-title":"Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8","volume":"202","author":"Vollmer","year":"2005","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.08.010_bib1345","first-page":"203","volume":"10","author":"Stevens","year":"1995","journal-title":"Anticancer Drug Design"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0630","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.4049\/jimmunol.175.3.1636","article-title":"TLR7\/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production","volume":"175","author":"Hart","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0635","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-11-1625","article-title":"VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC","volume":"18","author":"Lu","year":"2012","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0640","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/13543784.2011.583237","article-title":"VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis","volume":"20","author":"Horak","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0645","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1084\/jem.20041836","article-title":"Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin","volume":"201","author":"Coban","year":"2005","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0650","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin\u2013IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0655","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.vaccine.2010.11.003","article-title":"Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells","volume":"29","author":"Aichinger","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0660","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-3083.2008.02225.x","article-title":"IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice","volume":"69","author":"Olafsdottir","year":"2009","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0665","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1016\/j.vaccine.2006.03.071","article-title":"IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses","volume":"24","author":"Schellack","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0670","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.it.2005.08.006","article-title":"Of mice and man: TLR11 (finally) finds profilin","volume":"26","author":"Lauw","year":"2005","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0675","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.1109893","article-title":"TLR11 activation of dendritic cells by a protozoan profilin-like protein","volume":"308","author":"Yarovinsky","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0680","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","article-title":"TLR signaling pathways","volume":"16","author":"Takeda","year":"2004","journal-title":"Seminars in Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0685","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0690","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0695","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0700","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2796.2008.02029.x","article-title":"Autoimmune and inflammatory disorders and risk of malignant lymphomas \u2013 an update","volume":"264","author":"Smedby","year":"2008","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0705","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.gene.6364337","article-title":"Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk","volume":"7","author":"Nieters","year":"2006","journal-title":"Genes & Immunity"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0710","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0715","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/carcin\/bgn262","article-title":"A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma","volume":"30","author":"Purdue","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0720","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0725","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","article-title":"Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15","volume":"104","author":"Wysocka","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0730","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/CCID.S27482","article-title":"Emerging treatment options for early mycosis fungoides","volume":"6","author":"Fernandez-Guarino","year":"2013","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0735","first-page":"328","article-title":"New insights in the biology of Hodgkin lymphoma","volume":"2012","author":"K\u00fcppers","year":"2012","journal-title":"ASH Education Program Book"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0740","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Kuppers","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0745","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.intimp.2007.05.016","article-title":"Toll-like receptors in inflammation, infection and cancer","volume":"7","author":"Chen","year":"2007","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0750","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1164\/rccm.200404-491OC","article-title":"TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples","volume":"170","author":"Lazarus","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0755","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.gene.6364096","article-title":"Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma","volume":"5","author":"Tantisira","year":"2004","journal-title":"Genes & Immunity"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0760","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1196\/annals.1358.012","article-title":"TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation","volume":"1062","author":"Kesh","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0765","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.critrevonc.2007.04.009","article-title":"Marginal-zone lymphoma","volume":"63","author":"Ferreri","year":"2007","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0770","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0140-6736(93)91408-E","article-title":"The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori","volume":"342","author":"Hussell","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0775","first-page":"61","article-title":"Gastric MALT lymphoma and Helicobacter pylori","volume":"69","author":"Wotherspoon","year":"1996","journal-title":"Yale Journal of Biology and Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0780","doi-asserted-by":"crossref","first-page":"32552","DOI":"10.1074\/jbc.M305536200","article-title":"Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells","volume":"278","author":"Smith","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0785","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/IAI.73.3.1523-1531.2005","article-title":"Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways","volume":"73","author":"Torok","year":"2005","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0790","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/1042819050086451","article-title":"Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma","volume":"46","author":"Hellmig","year":"2005","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0795","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2006.06141.x","article-title":"Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma","volume":"134","author":"Forrest","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0800","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cncr.27792","article-title":"Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0805","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/gene.2011.59","article-title":"The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma","volume":"13","author":"Carvalho","year":"2012","journal-title":"Genes & Immunity"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0810","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/DAD.0b013e3182448f7c","article-title":"Mapping Toll-like receptor activity in different stages of cutaneous T-cell lymphoma","volume":"34","author":"Kado","year":"2012","journal-title":"American Journal of Dermatopathology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0815","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annual Review of Pathology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0820","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and Reed\u2013Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0825","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/jhg.2009.90","article-title":"Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study","volume":"54","author":"Mollaki","year":"2009","journal-title":"Journal of Human Genetics"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0830","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/erv.11.6","article-title":"Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma","volume":"10","author":"Klein-gonz\u00e1lez","year":"2011","journal-title":"Expert ReviewsVaccines"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0835","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clinical and Experimental Dermatology"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2013.08.010_bib0840","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0845","first-page":"3815","article-title":"IL-10 inhibits cytokine production by activated macrophages","volume":"147","author":"Fiorentino","year":"1991","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0850","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","article-title":"Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes","volume":"89","author":"Rousset","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0855","first-page":"4045","article-title":"Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines","volume":"158","author":"Beatty","year":"1997","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0860","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood.V94.8.2871","article-title":"Involvement of interleukin- 10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells","volume":"94","author":"Jones","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0865","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1182\/blood.V85.12.3423.bloodjournal85123423","article-title":"Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma","volume":"85","author":"Masood","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0870","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","article-title":"The clinical course of follicular lymphoma","volume":"18","author":"Rohatiner","year":"2005","journal-title":"Best Practice and Research Clinical Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0880","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/imt.12.38","article-title":"Combination strategies to enhance antitumor ADCC","volume":"4","author":"Kohrt","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0885","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.exphem.2007.08.012","article-title":"NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma","volume":"36","author":"Moga","year":"2008","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0890","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(01)00516-2","article-title":"Childhood acute lymphoblastic leukaemia\u2014current status and future perspectives","volume":"2","author":"Pui","year":"2001","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0895","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1182\/blood-2003-01-0338","article-title":"Classification of pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"102","author":"Ross","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0900","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1200\/JCO.2005.05.047","article-title":"Molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Armstrong","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0905","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0910","first-page":"1299","article-title":"Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia","volume":"90","author":"Bassan","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.010_bib1355","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-012-0122-5","article-title":"Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments","volume":"7","author":"Iacobucci","year":"2012","journal-title":"Current Hematologic Malignancy Reports"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0920","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital","volume":"104","author":"Pui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0925","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0930","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-012-0122-5","article-title":"Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments","volume":"7","author":"Iacobucci","year":"2012","journal-title":"Current Hematologic Malignancy Reports"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0935","first-page":"452","article-title":"Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia","volume":"132","author":"Corthals","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0940","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2004-06-2468","article-title":"CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response","volume":"105","author":"Reid","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0945","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2141.2002.03291.x","article-title":"ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype","volume":"116","author":"Alessandri","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0950","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V88.1.41.41","article-title":"Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen","volume":"88","author":"Cardoso","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0955","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0301-472X(99)00083-1","article-title":"Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells","volume":"27","author":"Yotnda","year":"1999","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0960","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0965","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/leu.2011.87","article-title":"Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses","volume":"25","author":"Fabricius","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0970","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"Bohnhorst","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0975","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2404226","article-title":"Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors","volume":"20","author":"Jego","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0980","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1034\/j.1600-065X.2003.00055.x","article-title":"The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease","volume":"194","author":"O\u2019Connor","year":"2003","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0985","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.coi.2004.02.001","article-title":"Plasma cell differentiation and multiple myeloma","volume":"16","author":"Shapiro-Shelef","year":"2004","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0990","first-page":"329","article-title":"Multiple myeloma\u2014an update on diagnosis and treatment","volume":"81","author":"Caers","year":"2008","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib0995","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.010_bib1360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3126\/jaim.v1i1.5837","article-title":"Epidemiology, biology, and outcome in multiple myeloma patients in different geographical areas of the world","volume":"1","author":"Saraf","year":"2012","journal-title":"Journal of Advances in Internal Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1005","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0268-960X(99)90014-0","article-title":"Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma","volume":"13","author":"Clark","year":"1999","journal-title":"Blood Reviews"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blad\u00e9","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1020","first-page":"41","article-title":"Clinical and laboratory features and prognostic implications in myeloma with and without renal impairment","volume":"39","author":"Grini\u016bte","year":"2003","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/10428199209049813","article-title":"Bone marrow microenvironment and the progression of multiple myeloma","volume":"8","author":"Caligaris-Cappio","year":"1992","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.08.010_bib1035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2141.2010.08284.x","article-title":"Expression and function of Toll-like receptors in multiple myeloma patients: Toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-\u03baB","volume":"150","author":"Xu","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(03)01195-1","article-title":"New insights into the pathophysiology of multiple myeloma","volume":"4","author":"Seidl","year":"2003","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1034\/j.1600-065X.2003.00053.x","article-title":"Novel therapeutic approaches for multiple myeloma","volume":"194","author":"Hideshima","year":"2003","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1050","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood.V99.10.3756","article-title":"Interleukin-21 is a growth and survival factor for human myeloma cells","volume":"99","author":"Brenne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1055","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/cncr.11072","article-title":"A review of the cytokine network in multiple myeloma","volume":"97","author":"Lauta","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1060","first-page":"282","author":"Jacobson","year":"1986","journal-title":"Immunosuppression and infection in multiple myeloma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1065","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.leukres.2010.06.002","article-title":"Toll-like receptors: expression and involvement in multiple myeloma","volume":"34","author":"Chiron","year":"2010","journal-title":"Leukemia Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1075","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","article-title":"Modulating vaccine responses with dendritic cells and Toll-like receptors","volume":"199","author":"Pulendran","year":"2004","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cellimm.2009.06.003","article-title":"A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines","volume":"259","author":"Assaf","year":"2009","journal-title":"Cellular Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1095","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1073\/pnas.0403744101","article-title":"CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells","volume":"101","author":"Sivori","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.11-1-21","article-title":"Chronic lymphocytic leukemia: recent advances in diagnosis and treatment","volume":"11","author":"Abbott","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1105","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ijc.24832","article-title":"Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation","volume":"126","author":"Rozkov\u00e1","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.08.010_bib1115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00277-012-1460-z","article-title":"Immunological aspects in chronic lymphocytic leukemia (CLL) development","volume":"91","author":"Garc\u00eda-Mu\u00f1oz","year":"2012","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1150","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2404061","article-title":"Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells","volume":"20","author":"Spaner","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1155","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","article-title":"B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides","volume":"11","author":"Jahrsd\u00f6rfer","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2404417","article-title":"The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease","volume":"21","author":"Longo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1165","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/0008-5472.CAN-06-2381","article-title":"Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1170","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/10428190500054426","article-title":"Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7\/8 agonist, imiquimod","volume":"46","author":"Spaner","year":"2005","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1175","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","article-title":"Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells","volume":"95","author":"Decker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1180","first-page":"81","article-title":"CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens","volume":"69","author":"Jahrsd\u00f6rfer","year":"2001","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1190","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.1305","article-title":"Immunity against solid tumors?","volume":"93","author":"Zinkernagel","year":"2001","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1200","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.molimm.2007.01.022","article-title":"TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance","volume":"44","author":"He","year":"2007","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1205","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/sj.leu.2403358","article-title":"Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy","volume":"18","author":"Hoogendoorn","year":"2004","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.critrevonc.2013.08.010_bib1210","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/blood-2009-03-213363","article-title":"Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells","volume":"115","author":"Liang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.coi.2005.02.007","article-title":"Pathogen recognition with Toll-like receptors","volume":"17","author":"Kawai","year":"2005","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1220","first-page":"708","article-title":"Imiquimod as an antiangiogenic agent","volume":"4","author":"Li","year":"2005","journal-title":"Journal of Drugs in Dermatology \u2013 JDD"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1225","first-page":"1656","article-title":"Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines","volume":"9","author":"Gitelson","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"23","key":"10.1016\/j.critrevonc.2013.08.010_bib1230","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy","volume":"18","author":"Riches","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1235","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00262-004-0626-5","article-title":"A phase I\/II trial of oxidized autologous tumor vaccines during the \u201cwatch and wait\u201d phase of chronic lymphocytic leukemia","volume":"54","author":"Spaner","year":"2005","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10428190109064586","article-title":"Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells","volume":"42","author":"Decker","year":"2001","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1245","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2119\/molmed.2011.00480","article-title":"Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors","volume":"18","author":"Ntoufa","year":"2012","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1250","first-page":"837","article-title":"Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-gamma-primed-macrophages","volume":"71","author":"Coelho","year":"2002","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1255","first-page":"83","article-title":"Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN","volume":"72","author":"Jahrsd\u00f6rfer","year":"2002","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1260","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/onc.2010.248","article-title":"Dichotomy in NF-\u03baB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering","volume":"29","author":"Tromp","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428194.2011.608451","article-title":"clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia","volume":"53","author":"Zent","year":"2012","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1270","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2002-01-0189","article-title":"Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin","volume":"101","author":"Decker","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.leu.2402389","article-title":"Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27","volume":"16","author":"Decker","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1280","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.4049\/jimmunol.176.6.3830","article-title":"Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity","volume":"176","author":"Tomic","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428199609051723","article-title":"New perspectives on the approach to chronic lymphocytic leukemia","volume":"22","author":"Goodman","year":"1996","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1290","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","article-title":"Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells","volume":"10","author":"Wang","year":"2003","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1295","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1300","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1189\/jlb.0604373","article-title":"Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells","volume":"77","author":"Jahrsd\u00f6rfer","year":"2005","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1305","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood.V99.4.1320.h8001320_1320_1326","article-title":"Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides","volume":"99","author":"Decker","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1310","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1073\/pnas.0631696100","article-title":"Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7","volume":"100","author":"Lee","year":"2003","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1315","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V84.10.3457.3457","article-title":"Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle","volume":"84","author":"Goodman","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1320","first-page":"44","article-title":"Recombinant toxins for the treatment of cancer","volume":"5","author":"Kreitman","year":"2003","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1325","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2005.02.012","article-title":"The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides","volume":"300","author":"Henault","year":"2005","journal-title":"Journal of Immunological Methods"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1330","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.yexmp.2010.08.003","article-title":"Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma","volume":"89","author":"Smith","year":"2010","journal-title":"Experimental and Molecular Pathology"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1335","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1600-0463.2012.02915.x","article-title":"Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFkappaB pathway","volume":"120","author":"Huang","year":"2012","journal-title":"APMIS: Acta Pathologica, Microbiologica, and Immunologica Scandinavica"},{"key":"10.1016\/j.critrevonc.2013.08.010_bib1340","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2119\/molmed.2011.00480","article-title":"Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors","volume":"18","author":"Ntoufa","year":"2012","journal-title":"Molecular medicine (Cambridge, MA)"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281300187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281300187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:38:09Z","timestamp":1596415089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281300187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":262,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S104084281300187X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.010","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}